Genmab CFO targets 39-percent recurring revenue growth in 2022

Anthony Pagano, CFO of Genmab, is expecting revenue growth of 39 percent from the products marketed by the company itself in 2022.

Photo: Lars Møller / Genmab / PR

In the current financial year, Danish biotech firm Genmab is hoping for a 39-percent growth in revenue from products it markets itself, meaning the company’s recurring revenue.

At a Wednesday teleconference in connection with Genmab’s full-year report, the company’s CFO Anthony Pagano spoke about Genmab’s hopes for recurring revenue.

The increase builds on recurring revenue growth of 48 percent in 2021 to around DKK 7bn (USD 1.1bn), which was driven by sales of cancer drug Darzalex from partner firm Johnson & Johnson, which contributed around DKK 6.1bn (USD 932m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs